Share on LinkedInShare on LinkedIn

ARTICLE · 17 NOVEMBER 2026

Expert's Own Admissions Limit His Trial Testimony In DNJ Patent Case

Fox Rothschild LLP
Fox Rothschild LLP
Contributor
Explore more from Fox Rothschild LLP

A recent New Jersey decision shows how an expert's own deposition admissions can shrink his trial testimony. Treating qualification as a threshold question under amended Federal Rule of Evidence 702, the Court confined a pharmaceutical patent expert to his core field — even though no jury would hear the case.

United StatesIntellectual Property

Key Points:

  • The Court treated an expert's qualifications as a threshold admissibility question for the judge, not a matter of weight or credibility — even in a bench trial.
  • Citing the expert's repeated deposition admissions that he lacked expertise in genetics, cancer cell biology, clinical trial interpretation, and cancer treatment, the Court limited the medicinal chemist's trial testimony to medicinal chemistry.
  • Hatch-Waxman and pharmaceutical patent litigants should take this as a reminder to match each expert's opinions to that expert's training.

A recent New Jersey decision shows how an expert's own deposition admissions can shrink his trial testimony. Treating qualification as a threshold question under amended Federal Rule of Evidence 702, the Court confined a pharmaceutical patent expert to his core field — even though no jury would hear the case.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from